A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With Myelodysplastic Syndrome (MDS)
Sponsor: Novartis Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAS4107
U.S. Govt. ID: NCT03946670
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to find out if the study drug MBG453 in combination with other drugs (decitabine or azacitidine) already commonly used to treat MDS is safe and has beneficial effects in people who have some types of MDS like you (intermediate, high, or very high risk MDS). Subjects will be administered the study treatment as indicated by your study doctor at the study clinic. The study treatment consists of decitabine or azacitidine (as decided by the study doctor) in combination with MBG453 or placebo. Subject may receive a placebo (liquid) in this study.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have diagnosis of Myelodysplastic syndrome (MDS)? Yes No
Do you have a hematopoietic stem-cell transplant planned? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE